Yoxlo’s patented research has unlocked the key to prolonging good health as we age
Even though we might be living longer than ever, many people still live their last years suffering from age-related diseases, such as heart disease, cancer, stroke, arthritis, Alzheimer’s disease, and diabetes. But Yoxlo is working to help us conquer common diseases and defy aging as we know it.
With a patented breakthrough in aging research, its labs are developing a health product that inhibits one protein that plays a pivotal role in aging. With less of the NLRP3 protein, we could all delay the inevitable, staying youthful and active for longer than ever before.
Supporting Yoxlo’s research and development is an investment in both your long-term health and in the science of healthy aging. Find out more about its unique strategy, dedicated to prolong good mental and physical health as we age.
our APPROACH
Biologically, humans should be able to live at least one hundred years in good mental and physical health. But today, only a tiny group of healthy centenarians—people who live in good health for at least one hundred years—achieve what we all want: a long healthspan that is active and disease-free. There is a unique reason why.
IT'S IN THEIR DNA
Healthy centenarians possess a unique genetic advantage: they naturally produce significantly lower levels of NLRP3, a key protein in the family responsible for inflammasomes. Among these proteins, NLRP3 is the most extensively researched, with high levels strongly linked to a wide range of age-related diseases. While elevated NLRP3 drives conditions that affect most people as they age, healthy centenarians remain largely free from these diseases, enjoying longer, healthier lives. Unlocking this genetic insight holds incredible potential to reshape the future of healthspan extension, offering new possibilities for longer, disease-free living for all.
CHRONIC INFLAMMATION AND AGING
When NLRP3 is activated, it triggers a cascade that drives inflammation, a natural response in our bodies designed to combat infection and repair damage. Normally, this process is beneficial. However, as people age, NLRP3 becomes chronically activated, leading to low-level, persistent inflammation. While often unnoticed, this gradual buildup silently wears down cells, organs, and tissues over time, contributing to the aging process and age-related diseases. Yet, this chronic inflammation is notably absent in healthy centenarians, who are genetically equipped to avoid this damaging cycle, allowing them to age with far fewer health complications.
A BREAKTHROUGH IN HEALTHSPAN EXTENSION
At Yoxlo, we’ve made a groundbreaking discovery: Youngenin, a patented mix of bio-active compounds, is designed to mimic the genetic advantage of high-performing centenarians. By inhibiting NLRP3, a key driver of chronic inflammation, Youngenin helps to counteract the effects of aging, improving muscle strength, enhancing immune function, and preserving cognitive health. This innovative approach targets the underlying processes that contribute to age-related decline, thereby extending healthspan.
At Yoxlo, we believe that Youngenin holds the potential to add more healthy, active years to life, helping people maintain their vitality and independence as they age.
With Youngenin, we can all invest in staying young and active for longer.
our mission
Yoxlo’s name incorporates everything the company strives for, living Younger for Longer, thanks to a groundbreaking X-factor: a health product that helps prolong the human healthspan at a cellular level.
Yoxlo was founded by Dr. Stef Verlinden, a research physician who specializes in gene therapy and cell engineering. Driven to help active people stay younger for longer, Yoxlo is developing a supplement with a compound proven to delay the low-grade inflammation leading to the diseases that often plague us as we grow older.
Supporting Yoxlo’s research and development is an investment in both your long-term health and in the science of healthy aging.
After years advancing scientific discovery, including researching gene therapy at Crucell (now Janssen Vaccines), the avid kite surfer, father, and researcher refuses to accept aging in the traditional sense. His life’s work researching rare, hereditary diseases, HIV, and Alzheimer’s lead to discovering how we can all age as well as high-performing centenarians, healthy and free of serious diseases. That is, with a healthy lifestyle and investing in healthy aging now, by preventing the onset of disease instead of treating it once it develops.
Verlinden has filed two patent applications in the United States and European Union for the technology and the method that helps lower a risk factor for disease.
We strive for a fantastic life for all people and will continue to develop novel insights and products to shrink the difference in healthspan between common people and high-performing centenarians.
Challenging the conventional
Yoxlo is a pioneer in the science of healthy aging.
Passion for progress
Our curiosity drives high expectations in research.
Life is extraordinary
Life is too short to be ordinary. Live it to the fullest.
funding
Yoxlo is actively seeking investors who are equally passionate about the science of better aging and prolonging their own good health. For updates on how you can support the next level of research on Youngenin and be among the first to enjoy its benefits, join our list or email us via the form below.
Subscribe to our Newsletter so you stay updated on our latest news and developments. Complete the form below to subscribe.
Contact
info@yoxlo.com
Adress
YOXLO B.V.
Biopartner 5 Building
De Limes 7
2343 DH Oegstgeest
© YOXLO, 2024 | Privacy Policy | Design by Ape to Zebra